Top

Published in:

Open Access 01-12-2018 | Research

IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients

Authors: Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sanchez Ciceron, Jenniffer Angulo, Marcelo López-Lastra, Paola Silvera, Adrian Canavesi, Carla Bianchi, Valentina Colistro, Juan Cristina, Nelia Hernandez, Pilar Moreno

Published in: Virology Journal | Issue 1/2018

Abstract

Background

Host single-nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) locus are associated with sustained virological response to antiviral therapy and with spontaneous Hepatitis C Virus (HCV) clearance. Prevalence of these SNPs varies depending on ethnicity. The impact of IL28B SNPs in HCV-infected patients is currently unknown in Uruguay. Therefore, the aim of this study was to evaluate and compare the distribution of polymorphisms in the IL28B gene (rs12979860 and rs8099917) among HCV-infected patients and healthy individuals in Uruguay and thus assess their possible association with the establishment of HCV infection.

Methods

DNA was recovered from 92 non-infected individuals and 78 HCV-infected patients and SNPs were determined by RFLP and allelic discrimination by real-time PCR.

Results

The distribution of rs12979860 genotypes for the infected population was 29.5%-CC, 47.4%-CT and 23.1%-TT and for the control group 45.7%, 42.4% and 11.9%, respectively. Prevalence in both infected and uninfected individuals is similar to that reported in other countries with admixed populations. The distribution of rs8099917 genotypes for the infected population was 57.7%-TT, 27.2%-TG and 14.1%-GG and for the control group 60.9%, 33.7% and 5.4%, respectively. The comparison of rs12979860 genotype distribution between the two populations evidenced a higher prevalence of the favourable genotype (CC) in the uninfected control group (p < 0.05). Additionally, results generated using logistic regression analysis show that individuals carrying rs12979860-TT or CT genotypes have a higher likelihood of developing chronic hepatitis upon infection with HCV, when compared to CC carriers, considering rs8099917 genotype as constant.

Conclusion

Patients with HCV infection have a statistically significant lower prevalence of the favourable rs12979860 genotype when compared to uninfected individuals; therefore we can establish that only IL28B rs12979860-CT and TT genotypes seem to contribute to the occurrence of chronic HCV infection in the cohort of Uruguayan population studied. Considering that a trend towards a higher frequency of “good” response genotypes was observed in responder patients, we believe that IL28B rs12979860 genotyping could be a useful tool for predicting different therapies outcome, including in the DAA era.

Available only for authorised users

2017 GHR. Geneva: World Health Organization. Geneva; 2017. licence: CC BY-NC-SA 3.0 IGO.

Hernandez N, Mescia G, Pollio C, Robaina G, Quintana L, Bianchi C. Effectiveness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice. Acta Gastroenterol Latinoam. 2010;40:117–21.PubMed

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (London, England). 2001;358:958–65. https://doi.org/10.1016/S0140-6736(01)06102-5.CrossRef

Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55. https://doi.org/10.7326/0003-4819-140-5-200403020-00010.CrossRefPubMed

Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350. https://doi.org/10.1136/gut.2005.076646.CrossRefPubMedPubMedCentral

Cornberg M, Hardtke S, Port K, Manns MP, Wedemeyer H, Standard HC. Of care. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Short guide to hepatitis C. Flying Publisher; 2012. p. 34–57.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401. https://doi.org/10.1038/nature08309.CrossRefPubMed

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4. https://doi.org/10.1038/ng.447.CrossRefPubMed

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9. https://doi.org/10.1038/ng.449.CrossRefPubMed

10.

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801. https://doi.org/10.1038/nature08463.CrossRefPubMedPubMedCentral

11.

Scherzer TM, Stättermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology. 2011;54:1518–26.CrossRefPubMed

12.

Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–45, 1345-7. https://doi.org/10.1053/j.gastro.2009.12.056.CrossRefPubMed

13.

Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained Virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120-9.e18. https://doi.org/10.1053/j.gastro.2010.04.013.

14.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:827.e1–827.

15.

Holmes JA, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat. 2012;19:677–84.CrossRefPubMed

16.

Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, et al. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. Spring. 2015;4:357. https://doi.org/10.1186/s40064-015-1137-x.CrossRef

17.

About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, et al. Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVRor BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20-CUPIC study. PLoS One. 2015;10:1–13.CrossRef

18.

Barreiro P, Vispo E, Poveda E, Fernández-Montero JV, Soriano V. Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the liver. Clin Infect Dis. 2013;56:560–6. https://doi.org/10.1093/cid/cis915.CrossRefPubMed

19.

D’Offizi G, Cammà C, Taibi C, Schlag M, Palma M, Demasi R, et al. Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection. New Microbiol. 2017;40:19–26.PubMed

20.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017;89:284–90.CrossRefPubMed

21.

Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.CrossRefPubMed

22.

Muir a J, Hu K-Q, Gordon SC, Koury K, Boparai N, Noviello S, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat. 2011;18:e134–43. https://doi.org/10.1111/j.1365-2893.2010.01402.x.CrossRefPubMed

23.

Trinks J, Hulaniuk ML, Redal MA, Flichman D. Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med. 2014;7:339–47.PubMedPubMedCentral

24.

Rajeevan H, Soundararajan U, Kidd JR, Pakstis AJ, Kidd KK. ALFRED: an allele frequency resource for research and teaching. Nucleic Acids Res. 2012;40(Database Issue):D1010–5.CrossRefPubMed

25.

Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M, et al. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol. 2012;11:876–81.PubMed

26.

Trinks J, Hulaniuk ML, Caputo M, Pratx LB, Ré V, Fortuny L, et al. Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. Pharmacogenomics J. 2014;14:549–54.CrossRefPubMed

27.

Angulo J, Pino K, Pavez C, Biel F, Labbé P, Miquel JF, et al. Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients. J Viral Hepat. 2013;20:263–72.CrossRefPubMed

28.

Venegas M, Villanueva RA, González K, Brahm J. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol. 2011;17:3636–9.CrossRefPubMedPubMedCentral

29.

Ridruejo E, Solano Á, Marciano S, Galdame O, Adrover R, Cocozzella D, et al. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 argentine patients treated with PEG IFN and ribavirin. Ann Hepatol. 2011;10:452–7.PubMed

30.

Bertol BC, Moreira S, Garcia RFL, Ferreira LE, Debortoli G, de Leite Pinho MS, et al. IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. Front Microbiol. 2015;6:1–8.CrossRef

31.

Cavalcante LN, Abe-Sandes K, Angelo ALD, Machado TMB, Lemaire DC, Mendes CMC, et al. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver Int. 2012;32:476–86.PubMed

32.

Salzano FM, Sans M. Interethnic admixture and the evolution of Latin American populations. Genet Mol Biol. 2014;37(1 SUPPL. 1):151–70.CrossRefPubMed

33.

Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and validation of a simple, rapid and inexpensive PCRRFLP method for genotyping of common IL28b polymorphisms: a useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon. 2012;12:190–5.PubMedPubMedCentral

34.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75. https://doi.org/10.1086/519795.CrossRefPubMedPubMedCentral

35.

R Core Team. R: A Language and Environment for statistical computing. R Foundation for Statistical Computing, Vienna. 2014. http://www.r-project.org/.

36.

Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.CrossRefPubMed

37.

Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One. 2012;7:1–8.

38.

Ramos JA, Ramos AL, Hoffmann L, Perez Rde M, HSM C, Ürményi TP, et al. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-rib. Mem Inst Oswaldo Cruz. 2012;107:888–92.CrossRefPubMed

39.

Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23–9.CrossRefPubMedPubMedCentral

40.

Castells M, Bello G, Ifrán S, Pereyra S, Boschi S, Uriarte R, et al. Epidemic history of major genotypes of hepatitis C virus in Uruguay. Infect Genet Evol. 2015;32:231–238. doi:https://doi.org/10.1016/j.meegid.2015.03.021.

41.

Taheri S, Aygen B, Korkmaz K, Yıldız O, Zararsız G, Canatan H. Characterization of the interleukin-28B gene rs12979860 C/T polymorphism in Turkish chronic hepatitis C patients and healthy individuals. Balkan Med J. 2015;32:147–55.CrossRefPubMedPubMedCentral

42.

Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52:33–7.CrossRefPubMed

43.

Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo SI, Waked I, et al. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol Int. 2015;9:251–7.CrossRefPubMed

44.

Sharafi H, Moayed Alavian S, Behnava B, Pouryasin A, Keshvari M. The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C; a case-control study. Hepat Mon. 2014;14:e22649.CrossRefPubMedPubMedCentral

45.

Mah Y-H, Liu C-H, Chen C-L, Tseng T-C, Liu C-J, Chen P-J, et al. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. J Formos Med Assoc. 2016;115:953–60. https://doi.org/10.1016/j.jfma.2016.07.013.CrossRefPubMed

46.

de Seixas Santos Nastri AC, de Mello Malta F, Diniz MA, Yoshino A, Abe-Sandes K, Dos Santos SE, et al. Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil. Arch Virol. 2016;161:1477–84.CrossRefPubMed

47.

Heo NY, Lim YS, Lee W, Oh M, An J, Lee D, et al. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. Clin Mol Hepatol. 2014;20:177–84. https://doi.org/10.3350/cmh.2014.20.2.177.CrossRefPubMedPubMedCentral

48.

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology. 2011;53:746–54. https://doi.org/10.1002/hep.24154.CrossRefPubMed

49.

Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals. Hepat Mon. 2012;12:e8387.PubMedPubMedCentral

50.

Minakari M, Golshani M, Yaran M, Ataei B. Prevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, Iran. Adv Biomed Res. 2016;5:90.CrossRefPubMedPubMedCentral

51.

Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, De ZG, et al. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis. 2015;16:90–7. https://doi.org/10.1111/1751-2980.12202.CrossRefPubMed

52.

Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, et al. IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational gen-C study. Spring. 2016;5:1990. https://doi.org/10.1186/s40064-016-3663-6.CrossRef

Title: IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients
Authors: Natalia Echeverría
Daniela Chiodi
Pablo López
Adriana Sanchez Ciceron
Jenniffer Angulo
Marcelo López-Lastra
Paola Silvera
Adrian Canavesi
Carla Bianchi
Valentina Colistro
Juan Cristina
Nelia Hernandez
Pilar Moreno
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2018
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-018-0946-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Molecular characterization and phylogenetic analysis of a dengue virus serotype 3 isolated from a Chinese traveler returned from Laos

Detection of mammalian orthoreovirus type-3 (Reo-3) infections in mice based on serotype-specific hemagglutination protein sigma-1

The eukaryotic translation elongation factor 1A regulation of actin stress fibers is important for infectious RSV production

Geographical distribution and relative risk of Anjozorobe virus (Thailand orthohantavirus) infection in black rats (Rattus rattus) in Madagascar

Virome analyses of Hevea brasiliensis using small RNA deep sequencing and PCR techniques reveal the presence of a potential new virus

Bat lung epithelial cells show greater host species-specific innate resistance than MDCK cells to human and avian influenza viruses

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page